Clinical Trial · NCT07400224

Clinical Application of Al18F-NOTA-FAPI-04 PET/CT or PET/MRI Imaging in Malignant Tumor,Cardiovascular or Immune Disease

Overview

This prospective, single-center study investigates the biodistribution, dosimetry, safety, diagnostic performance of Al18F-NOTA-FAPI PET imaging in patients with malignant tumor,cardiovascular or immune disease. And evaluates the potential of Al18F-NOTA-FAPI PET imaging in Clinical treatment strategy guidance.

Phase

Phase 1/2

Contacts

Li Huo, MD (CONTACT)

huoli@pumch.cn

+86 18612672038

Xueqian Yang, MS (CONTACT)

yangxq202508@163.com

+86 18801349606

ClinicalTrials.gov

NCT07400224

Drug / Compound

FAPI-04

Isotope(s):
Target(s):
  • FAP
Ligand Class: Small Molecules
Chelator: NOTA